Treatment of benign prostatic hyperplasia in Australia - some economic considerations

Hailey D, Dankiw W, Coochey J
Record ID 31995000068
Authors' objectives:

To provide preliminary estimates of the cost to health programs of treating BPH using different options, and of the cost of BPH to the community.

Authors' results and conclusions: Clinical: About 35,000 men are admitted to hospital each year with a diagnosis of BPH, and there are approximately 25,000 surgical procedures (TURP). Economic: Total cost to health programs over five years for the annual cohort of cases treated with TURP is estimated as $123 M, taking into account retreatment. Comparative costs of options which include other forms of treatment are $90M for the thermotreatment, $55M for lasers, $136M for drugs and $127M for stents. If the wider burden to the community is considered, taking account of non-treated cases and of lost production and lost leisure time, the impact using TURP only as treatment is up to $186M plus 0.61M days of lost leisure whose monetary value is uncertain. Comparative figures for other options include: thermotreatment $140M + 0.4M days; laser $100M + 0.16M days; drugs $163M, 0.53M days.
Authors' recommendations: The estimates suggest that use of thermotreatment and lasers may offer an advantage over TURP. However, the results are sensitive to a number of factors, particularly the length of hospital stay and convalescence after TURP, and machine utilisation and costs of disposables for the thermotreatment and laser options. There will be further impact of the newer methods through their use for patients who are not candidates for surgery. Quality of life issues, which are not considered in this analysis, are likely to be significant.
Project Status: Completed
URL for project:
Year Published: 1995
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Australia
MeSH Terms
  • Prostatic Hyperplasia
Organisation Name: Australian Health Technology Advisory Committee
Contact Address: Naarilla Hirsch, Australian Institute of Health and Welfare Health Technology Unit, GPO Box 570, Canberra, ACT, 2601, Australia
Copyright: Australian Institute of Health and Welfare (AHTAC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.